

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>NUSSDORF GLENN H</u> <hr/> (Last) (First) (Middle) <u>35 SAWGRASS DRIVE</u> <hr/> (Street) <u>BELLPORT NY 11713</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Organogenesis Holdings Inc. [ ORGO ]</u> <hr/> 3. Date of Earliest Transaction (Month/Day/Year) <u>09/03/2019</u> <hr/> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	09/03/2019		P		50,000 <sup>(1)</sup>	A	\$4.3786 <sup>(2)</sup>	67,896,723	D	
Class A Common Stock	09/03/2019		P		100 <sup>(3)</sup>	A	\$4.25	67,896,823	D	
Class A Common Stock	09/04/2019		P		50,000 <sup>(1)</sup>	A	\$4.6238 <sup>(4)</sup>	67,946,823	D	
Class A Common Stock	09/05/2019		P		5,000 <sup>(5)</sup>	A	\$4.5328 <sup>(6)</sup>	67,951,823	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>NUSSDORF GLENN H</u> <hr/> (Last) (First) (Middle) <u>35 SAWGRASS DRIVE</u> <hr/> (Street) <u>BELLPORT NY 11713</u> <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person \*

Wisdom Starr

(Last) (First) (Middle)

44 WILSON STREET

(Street)

HARTSDALE NY 10530

(City) (State) (Zip)

**Explanation of Responses:**

1. The reported securities were purchased and are held directly by Glenn H. Nussdorf, who is a member of the Group (as defined below).
2. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from \$4.28 to \$4.48, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. The reported securities were purchased and are held directly by Dennis Erani, who is a member of the Group.
4. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from \$4.37 to \$4.92, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.
5. The reported securities were purchased and are held directly by Albert Erani, who is a member of the Group.
6. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from \$4.52 to \$4.55, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4.

**Remarks:**

Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016 and GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, referred to collectively as the "Controlling Entities", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Controlling Entities with respect to four directors of the Issuer and qualifies the Issuer as a "controlled company" under the Nasdaq listing rules. As a result of the Stockholders' Agreement, the reporting persons may be deemed to be members of a group (the "Group") holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. This is Form 4 No. 2 of 2 filed for the Controlling Entities.

/s/ Stacie S. Aarestad  
Attorney-in-Fact

09/05/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**